Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 532531 | NSE Symbol : STAR | ISIN : INE939A01011 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
24-Jan-2025	30-Jan-2025	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday January 30 2025 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from January 1 2025 and shall open after 48 hrs post declaration of un-audited financial results by the Company. Outcome of Board Meeting - Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2024. Appointment of Ms. Mukta Arora (DIN: 07225715) as Independent Director of the Company effective February 1, 2025. Change in designation of Mr. Arun Kumar (DIN: 00084845) from Executive Chairperson to Non-Executive Chairperson of the Company effective April 5, 2025. Change in Registered office of the Company (As Per BSE Announcement dated on 30.01.2025)
26-Nov-2024	26-Nov-2024	Scheme of Arrangement	Intimation of Record Date under Regulation 42 of SEBI Listing Regulations
18-Oct-2024	24-Oct-2024	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/10/2024 inter alia to consider and approve This is to inform you that meeting of Board of Directors of the Company is scheduled to be held on Thursday October 24 2024 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2024 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from October 1 2024 and shall open after 48 hrs post declaration of financial results by the Company. The above information will also be available on the website of the Company at www.strides.com. This is for your kind information and record purposes. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2024. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half-year ended September 30, 2024 (As Per BSE Announcement Dated on 24.10.2024)
22-Jul-2024	29-Jul-2024	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2024 inter alia to consider and approve Announcement of Board meeting under Regulation 29 of SEBI Listing Regulations. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2024. (As Per BSE Announcement dated on 29.07.2024)
14-May-2024	22-May-2024	Final Dividend	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 22/05/2024 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - May 22, 2024 Allotment of Shares Grant of Stock Options under Strides ESOP Plan Recommendation of Final Dividend for FY ended March 31, 2024 Outcome of Board Meeting - May 22, 2024 - Change in Board composition and Management Outcome of Board Meeting - May 22, 2024 - Change in Management (As Per BSE Announcement Dated on 22.05.2024)
22-Jan-2024	30-Jan-2024	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2024 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday January 30 2024 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2023 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and nine months ended December 31, 2023 Appointment of Mr. Ameet P Hariani (DIN: 00087866) as Independent Director of the Company effective February 1, 2024 (As Per BSE Announcement Dated on 30/01/2024)
02-Jan-2024	02-Jan-2024	Investments	Investment in AMP Energy
20-Oct-2023	30-Oct-2023	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/10/2023 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday October 30 2023 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2023 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. This is for your kind information and record purposes. Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter and half year ended September 30, 2023. (As per BSE Announcement Dated on 30/10/2023)
20-Sep-2023	25-Sep-2023	Scheme of Arrangement	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/09/2023 inter alia to consider and approve We refer to Companys announcement of August 2 2023 as part of Q1 FY24 Earnings Presentation about our intent to combine CDMO interests of the group to become one of Indias top specialty pharmaceuticals CDMOs. We now wish to inform you that a board meeting of the Company is scheduled to be held on Monday September 25 2023 to consider the above proposal. The Company will also host a call on Monday September 25 2023 at 17:00 hrs IST to interact with the investors in connection with the above proposal. Intimation of Scheme of Arrangement, pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations) Scheme of Arrangement (As per BSE Announcement Dated on 25/09/2023)
07-Sep-2023	07-Sep-2023	Acquisitions	As part of internal restructuring within the group, Board of Directors of the Company at their meeting held on September 7, 2023 have approved acquisition of 100% shareholding in Strides Pharma Services Private Limited (SPSPL). SPSPL is currently a WOS of Arco Lab Private Limited, a WOS of the Company. Post the said acquisition, SPSPL shall be a WOS of the Company. Disclosure under Regulation 30 of SEBI Listing Regulations read with SEBI Circular of July 13, 2023 relating to the proposed transaction is enclosed.
25-Jul-2023	02-Aug-2023	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/08/2023 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - Un-audited Financial Results (Standalone & Consolidated) for quarter ended June 30, 2023. Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (As Per BSE Announcement Dated on 02/08/2023)
18-May-2023	25-May-2023	Final Dividend	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 inter alia to consider and approve Announcement of Board Meeting under Regulation 29 of SEBI Listing Regulations Outcome of Board Meeting - Audited Financial Results (Standalone & Consolidated) for quarter and year ended March 31, 2023 (As per BSE Announcement Dated on 25/05/2023)
17-Jan-2023	24-Jan-2023	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/01/2023 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Tuesday January 24 2023 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and nine months ended December 31 2022 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed and shall open after 48 hrs post declaration of financial results by the Company. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and nine months ended December 31, 2022 (As Per BSE Announcement Dated on 24/01/2023)
07-Nov-2022	14-Nov-2022	Quarterly Results	Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2022 inter alia to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Monday November 14 2022 to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter and half year ended September 30 2022 amongst other matters. Further as per provisions of the Companys Code of Conduct for Prohibition of Insider Trading trading window for Designated Persons of the Company is closed from Saturday October 1 2022 upto Wednesday November 16 2022 (both days inclusive). This is for your kind information and record purposes. Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter and half year ended September 30, 2022 Pursuant to the recommendation of Nomination and Remuneration Committee, the Board of Directors of the Company in their meeting held today i.e., November 14, 2022, has granted 42,500 stock options to eligible employees under the Strides ESOP Plan 2016 at Rs. 240/- per option (exercise price). The shares covered by such options are 42,500 equity shares. The vesting period of these options are in a phased manner over a period of 3 years. The options are exercisable within a period of 12 months (exercisable in not more than two tranches) from the date of vesting. Allotment of shares under Strides ESOP Plan 2016 This is to inform you that Mr. Deepak Calian Vaidya (DIN: 00337276), Non-Executive Director of the Company has communicated his decision to step down from Directorship of the Company with effect from closing business hours of November 14, 2022, due to pre-occupation. Mr. Vaidya was associated with Strides since January 1998 and has made significant contributions in laying a solid foundation for taking Strides to the next level of growth with compliance and integrity as key pillars. Strides has benefited immensely by his experience and guidance at many junctures. Board of Directors at their meeting held today placed on record their sincere appreciation for the valuable contributions made by Mr. Vaidya during his long and distinguished association with the Company and wished him the very best. Information as required under Regulation 30 of Listing Regulations, read with SEBI Circular No. CIR/ CFD/ CMD/ 4/ 2015 dated September 9, 2015 is enclosed. (As Per BSE Announcement Dated on 14.11.2022)
22-Jul-2022	29-Jul-2022	Quarterly Results	Quarterly Results Strides Pharma Science Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2022 ,inter alia, to consider and approve This is to inform you that a meeting of Board of Directors of the Company is scheduled to be held on Friday, July 29, 2022, to consider and approve the un-audited financial results (standalone and consolidated) of the Company for the quarter ended June 30, 2022, amongst other matters. Further, as per the provisions of the Company's Code of Conduct for Prohibition of Insider Trading, trading window for designated persons of the Company is closed from Friday, July 1, 2022, upto Sunday, July 31, 2022 (both days inclusive). This is for your kind information and record purposes. (As Per BSE Announcement Dated on 22.07.2022) Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2022 (As per BSE Announcement Dated on 29/07/2022)

1 2

LOGIN HERE

Strides Pharma Science Ltd

Board Meeting